Clinical trial of oxaliplatin combined with capecitabine in the treatment of advanced colon cancer
10.13699/j.cnki.1001-6821.2016.14.011
- VernacularTitle:奥沙利铂联合卡培他滨治疗晚期结肠癌的临床研究
- Author:
Yue-Wei MAO
1
;
Song-Peng YANG
;
Lei GAO
;
De-Sheng HU
;
Ning-Wei YIN
;
Han-Song LIU
Author Information
1. 郑州大学 附属郑州中心医院 胃肠血管外科
- Keywords:
oxaliplatin;
capecitabine;
colon cancer;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(14):1286-1288,1292
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of oxaliplatin combined with capecitabine in the treatment of advanced colon cancer.Methods A total of 40 patients with advanced colon cancer were randomly divided into control group ( n=20 ) and treatment group (n=20).Control group was given 130 mg? m-2 oxaliplatin, intrave-nous infusion , day 1 and 500 mg? m -2 fluorouracil , intravenous infu-sion, days 1 -5, for three cycles with 14 days per cycle.Treatment group was treated with 130 mg? m-2 oxaliplatin , intravenous infusion , day 1 and 1250 mg? m-2 capecitabine , days 1-14 , for two cycles with 21 days per cycle.The clinical efficacy , levels of serum ovarian cancer gene protein, oncogene Ras product P21 protein, proto oncoprotein and interleukin 6 , the incidence of adverse drug reactions were compared between two groups.Results After treatment , the total effective rates of treatment and control group were 85.00%( 17/20 ) , 45.00%( 9/20 ) , respectively , with statistically significant difference ( P <0.05 ) .After treatment , the level of serum ovarian cancer gene protein in treatment group was significantly higher than that in control group [(25.65 ±3.14) vs (17.45 ±2.27)μg? mL-1, P<0.05].After treatment, among the treatment and control group, the levels of serum oncogene Ras product P21 protein were (8.54 ±1.23), (15.67 ±2.11)ng? mL-1, proto oncoprotein were (1.76 ±1.15), (19.54 ±2.31)ng? mL-1 and the levels of interleukin 6 were (108.62 ±10.77), (122.45 ±14.25 ) pg? mL-1 , also, the indexes in treatment group after treatment were significantly lower than those in control group ( P<0.05 ) .The adverse drug reactions were based on the symptoms of nervous system , digestive system and skin for two groups.Also, the incidence of adverse drug reactions in control group was 30.00%, treatment group was 15.00%, the difference had no statistically significant difference ( P>0.05 ) .Conclusion Oxaliplatin combined with capecitabine has a definitive clinical efficacy and safety for the treatment of advanced colon cancer , which can de-crease the levels of serum oncogene Ras product P 21 protein, proto oncoprotein and interleukin 6 and improve the level of serum ovarian cancer gene protein .
